CD8A and neoplasm: Exosomal PD-L1 from tumor cells systemically suppress antitumor immunity by directly binding to PD-1-expressing CD8+ T cells, and the level of plasma exosomal PD-L1 may predict the clinical effectiveness of anti-PD-1 therapy [48].